Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Melcher

Showing results (131-140 of 134) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 134 results.
Journal for Immunotherapy of Cancer|March 3, 2026
Effects of oncolytic immunotherapy with RP1 (vusolimogene oderparepvec) on immune cells mediate responsiveness to anti-PD-1 via STING-mediated interferon signalingVictoria Roulstone, Joan Kyula, Elizabeth Appleton, et al.
Nature Communications|March 6, 2026
Necroptosis in both tumour and stromal compartments determines responsiveness to immunogenic cell death-based immunotherapyWinnie Fernando, Jarama Clucas, Alberto Rizzo, et al.
Oncoimmunology|June 26, 2023
Updates on radiotherapy-immunotherapy combinations: Proceedings of 6<sup>th</sup> annual ImmunoRad conferenceFabiana Gregucci, Sheila Spada, Mary Helen Barcellos-Hoff, et al.
Nature Communications|April 8, 2022
Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapyMarie-Eve Wedge, Victoria A Jennings, Mathieu J F Crupi, et al.
Pageof 14

Showing results (131-140 of 134) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 134 results.
Journal for Immunotherapy of Cancer|March 3, 2026
Effects of oncolytic immunotherapy with RP1 (vusolimogene oderparepvec) on immune cells mediate responsiveness to anti-PD-1 via STING-mediated interferon signalingVictoria Roulstone, Joan Kyula, Elizabeth Appleton, et al.
Nature Communications|March 6, 2026
Necroptosis in both tumour and stromal compartments determines responsiveness to immunogenic cell death-based immunotherapyWinnie Fernando, Jarama Clucas, Alberto Rizzo, et al.
Oncoimmunology|June 26, 2023
Updates on radiotherapy-immunotherapy combinations: Proceedings of 6<sup>th</sup> annual ImmunoRad conferenceFabiana Gregucci, Sheila Spada, Mary Helen Barcellos-Hoff, et al.
Nature Communications|April 8, 2022
Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapyMarie-Eve Wedge, Victoria A Jennings, Mathieu J F Crupi, et al.
Pageof 14